ClinicalTrials.gg
RecruitingNCT07132970LICOSARHUpdated Jun 9, 2026

Leakage Rate of Ileo-COlic Sutured Anastomosis After Right Hemicolectomy

An observational study in Anastomotic Leak, Colon Cancer and Right Hemicolectomy, sponsored by Aesculap AG. Recruiting at 4 sites in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-09.

Sponsored by Aesculap AG (part of B. Braun) · Observational

How we know

From the registry’s dates

  • Started Jan 2026; still recruiting 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
249
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 13 studies in Anastomotic Leak with a site in Germany — 1 open to participants now, 2 under way, none of them phase 3. Anastomotic Leak · Germany.

Started
2026
the only one that year
Observational
4 of 13
1 open now
Registered
13th of 13
by date
Lead sponsor
1 of 13
Aesculap AG

Among the 13 studies in Anastomotic Leak with a site in Germany, this one is the only one that started in 2026, is one of 4 observational ones, and was the 13th registered.

Anastomotic Leak

240 studies on the registry are indexed under Anastomotic Leak; 72 are open to participants now.

Browse Anastomotic Leak studies →

Open to participants now

1 of the 13 studies in Anastomotic Leak with a site in Germany is open now.

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 45 Anastomotic Leak studies recruiting now, 23 (51%) set no upper age limit and 11 (24%) stop at 75 or younger; 1 takes children under 18; 1 takes healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies in Anastomotic Leak with a site in Germany, or all of them as a file.
02

Study summary

The primary aim of the study is to show that the ileo-colic anastomosis leakage rate until the first 30 days after surgery using MonoPlus® suture material for anastomosis construction after right hemicolectomy is not inferior to the anastomosis leakage rate published in the literature for totally handsewn or stapled-handsewn ileo-colic anastomosis.

Read the detailed description

The study will include patients with right colon cancer, treated with elective colectomy and with local curative intention, in whom primary anastomosis with no protective stoma will be performed. Right colectomy is defined as a resection of terminal 10 cm of ileum, the cecum, the ascending right colon, and right third or half of the transverse colon followed by ileo-colostomy.The anastomosis leakage rate after right-sided hemicolectomy is the most important complication, because it leads to further morbidity of the affected patients. The anastomosis leakage rate ranges between 1-10% depending on the study population (cancer patients vs. non-cancer patients) and the type of anastomosis.

03

Conditions studied

  • Anastomotic Leak
  • Colon Cancer
  • Right Hemicolectomy
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Patients undergoing elective, primary open or laparoscopic right hemicolectomy or right extended hemicolectomy for malignancy with the creation of an intracorporeal or extracorporeal ileo-colic anastomosis.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients undergoing a primary, elective either open or laparoscopic right hemicolectomy or right extended hemicolectomy due to with the creation of an intracorporeal or extracorporeal ileo-colic anastomosis.
  • Either complete hand-sewn anastomosis or partial sutured anastomosis (e.g. combination of stapling and suturing)
  • Open or laparoscopic as well as conversion from open to laparoscopic surgery
  • Absence of peritoneal carcinomatosis
  • Absence of vascular, nervous or bone infiltration
  • Age ≥ 18 years
  • Written data protection declaration (Written )

Exclusion criteria

Exclusion Criteria:

  • Left hemicolectomy or left extended hemicolectomy or sigma resection
  • Inflammatory bowel disease (e.g. Crohn´s disease)
  • Emergency surgery
  • Previous abdominal surgery with bowel resection
  • Re-operation of an anastomosis (anastomosis revision surgery)
  • Need for stoma creation
  • Non-compliant patients
  • Participation in an interventional randomized controlled study (RCT)
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
249 participants (estimated)
Patient registry
No

Interventions

  • DeviceMonoplus Suture Material

    Ileocolic Anastomosis Construction using Monoplus Suture Material after open or laparoscopic surgery

06

What researchers measure

Primary outcomes

  1. Rate of anastomosis leakage

    An anastomosis leak is defined as " leak of luminal contents from a anastomotic site between two hollow viscera" diagnosed (1) radiologically, by a radiographic enema with hydro soluble contrast or by computerized tomography with the presence of intra-abdominal collection adjacent to the anastomosis; (2) clinically with evidence of extravasation of bowel content or gas through a wound or drain; (3) by endoscopy, or (4) intraoperatively. Anastomosis leak will be classified and graded according to Clavien-Dindo. Grade I: Anastomosis leakage requiring no active intervention (e.g. antibiotics) Grade II: Anastomosis leakage requiring active radiological intervention but manageable without surgical intervention. Grade III: Anastomosis leakage requiring surgical re-intervention. Grade IV: Anastomosis leakage leading to life-threatening condition requiring IC /ICU management Grade V: Anastomosis leakage leading to death of the patient

    Time frame: until 30 days postoperatively

Secondary outcomes

  1. Rate of complications

    Stenosis * bleeding * hemmorage * obstruction * intradominal abszess * ileus * peritonitis * sepsis

    Time frame: discharge, 30 days postoperatively, 1 year postoperatively

  2. Mortality rate

    Time frame: 30 days postoperatively, 1 year postoperatively

  3. Surgical Site infection rate

    Superficial Surgical Site Infection and deep Surgical Site Infection rate according to CDC

    Time frame: 30 days and 12 months after surgery

  4. Length of hospital stay

    Time frame: day of discharge after surgery

  5. Handling of the used suture material

    Different dimensions rated by the surgeon using 5-point Likert scale. (1= best to 5=worse) A 5-point Likert scale is a survey tool that allows respondents to express their level of agreement or disagreement with a statement, providing nuanced feedback through five ordered response options. Structure of a 5-Point Likert Scale A typical 5-point Likert scale includes the following response options: Strongly Disagree: Indicates a firm rejection of the statement. Disagree: Shows a general opposition to the statement, but less intense than "Strongly Disagree." Neither Agree Nor Disagree: Represents a neutral position, suggesting indecision or a balanced view. Agree: Expresses support for the statement, but not with full intensity. Strongly Agree: Demonstrates strong approval or endorsement of the statement. 2

    Time frame: interoperatively

  6. Patient satisfaction

    Assessment of patient satisfaction using 100 point scale (1 lowest- 100 highest satisfaction)

    Time frame: 30 days postoperavely, 12 months postoperatively

  7. Quality of Life, using EQ5D5L

    EQ-5D-5L consists of 2 pages - descriptive system and the EQ visual Analogue scale (EQ-VAS). The descriptive system comprises 5 dimensions (mobility, self-care, usual activities, pain/discomfort, anxiety/depression). Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems and extreme problems. The EQ VAS records the respondents self-rated health on a 20 cm vertical, visual analogue scale with endpoints labelled "the best health you can imagine" and " the worst health you can imagine"

    Time frame: preoperatively, 30 day postoperatively and 12 months postoperatively

  8. Bowel function assessment

    Low Anterior Rectum Syndrome (LARS) questionnaire, assessed by the patient. The LARS Score was developed in 2012 and represents an international, validated, simple and quick instrument to assess bowel function and allows quantitative evaluation of severity of functional defects. It consists of 5 questions with a score that ranges from 0 to 42 points, with classification of patients into: no LARS (0-20), minor LARS (21-29) or major LARS (30-42 points). The five very disabling bowel symptoms of LARS score (any flatus or liquid incontinence, altered stool frequency, faecal clustering and faecal urgency) will be analysed and rated by the patients, because of their known negative influence on quality of life.

    Time frame: Day of discharge after surgery, 30 days postoperatively, 1 year postoperatively

  9. Hernia rate

    Hernia will be evaluated according to the EHS classification (European Hernia Society), Incisional hernia is defined as an "abdominal wall gap with or without bulge in the area of a postoperative scar perceptible or palpable by clinical examination or imaging" according to the definition to the European Hernia society

    Time frame: 12 months postoperatively

07

Study locations

4 of 4 sites recruiting
  • Alb-Fils-Klinikum Göppingen, Dept. General Surgery
    Göppingen, Baden-Wurttemberg 73035, Germany
    Recruiting
    • Stefan Riedl, Prof.Dr.med · Contact
  • Diakonie-Klinikum Landkreis Schwäbisch Hall, Dept. General Surgery
    Schwäbisch Hall, Baden-Wurttemberg 74523, Germany
    Recruiting
    • Markus Golling, Prof. Dr. · Contact
  • Städtisches Klinikum Lüneburg, Dept. General Surgery
    Lüneburg, Lower Saxony 21339, Germany
    Recruiting
    • Tobias Rose, Dr. · Contact
  • AGAPLESION ELISABETHENSTIFT, Klinik für Allgemein- und Viszeralchirurgie
    Darmstadt, 64287, Germany
    Recruiting
    • Guido Woeste, Prof. Dr. · Contact
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2026 (actual). Primary completion is estimated for Jul 2027, 18 months after the start.

Of 52 observational studies under Anastomotic Leak, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 98. This study's planned 18 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 2, 2025
First posted
Aug 20, 2025
StartActual
Jan 26, 2026
Primary completionEst.
Jul 2027
CompletionEst.
Mar 2028
Last update
Jun 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 9, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07132970
Lead sponsor
Aesculap AG
Responsible party
Sponsor
First posted
Aug 20, 2025
Start date
Jan 26, 2026
Primary completion
Jul 2027 (estimated)
Completion
Mar 2028 (estimated)
Last update
Jun 9, 2026

Study contacts

Petra Baumann, Dr.
Contact
studies@aesculap.de
+497461-95 ext. 0
Markus Golling, Prof. Dr.
study chair · Diak Klinikum Landkreis Schwäbisch Hall, Dept. of General Surgery

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion